{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:59:50Z","timestamp":1775001590008,"version":"3.50.1"},"reference-count":43,"publisher":"University of Tokushima Faculty of Medicine","issue":"1.2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Invest."],"published-print":{"date-parts":[[2022]]},"DOI":"10.2152\/jmi.69.80","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T22:12:03Z","timestamp":1650579123000},"page":"80-85","source":"Crossref","is-referenced-by-count":11,"title":["Relationship between quality of life and clinical factors in inpatients with schizophrenia"],"prefix":"10.2152","volume":"69","author":[{"given":"Yoshimune","family":"Ishii","sequence":"first","affiliation":[{"name":"Department of psychiatry, Jounan Hospital, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Tomotake","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Department of Mental Health, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatomo","family":"Aono","sequence":"additional","affiliation":[{"name":"Department of psychiatry, Jounan Hospital, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koushirou","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of psychiatry, Jounan Hospital, Tokushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"925","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Revicki DA, Murray M:Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs 1:465-476, 1994","DOI":"10.2165\/00023210-199401060-00008"},{"key":"2","unstructured":"2. Awad AG, Voruganti LNP, Heslegrave RJ:A conceptual model of quality of life in schizophrenia:description and preliminary clinical validation. Quality of Life Research 6:21-26, 1997"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lally J, MacCabe JH:Antipsychotic medication in schizophrenia:a review. British Medical Bulletin 114:169-179, 2015","DOI":"10.1093\/bmb\/ldv017"},{"key":"4","unstructured":"4. Tomotake M, Iga J, Kinouchi S, Shibuya S, Motoki I, Sumitani S, Yamauchi K, Kotani Y, Kaneda Y, Taniguchi T, Ishimoto Y, Ueno S, Ohmori T:Subjective and objective quality of life in outpatients with schizophrenia. Annual Review of Psychopharmacology 36:145-152, 2004 (in Japanese)"},{"key":"5","unstructured":"5. Kunikata H, Mino Y:Quality of life and schizophrenia a review of the literature. Japan Journal of Public Health 50:377-388, 2003 (in Japanese)"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Larsen EB, Gerlach J:Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatrica Scandinavica 93:381-388, 1996","DOI":"10.1111\/j.1600-0447.1996.tb10664.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lehman AF:The well-being of chronic mental patients. Arch Gen Psychiatry 40:369-373, 1983","DOI":"10.1001\/archpsyc.1983.01790040023003"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lehman AF:A quality of life interview for the chronically mentally ill. Evaluation and Program Planning 11:51-62, 1998","DOI":"10.1016\/0149-7189(88)90033-X"},{"key":"9","unstructured":"9. Osada H, Tateyama M, Ketsuka T, Satomura K, Matsumoto H, Miyata R, Fujii Y, Noguchi H, Yamanaka K, Tsugeno M:Quality of Life in Schizophrenic Patients (\u2161). The Journal of Tokyo Academy of Health Sciences 1:107-110, 1998 (in Japanese)"},{"key":"10","unstructured":"10. Tomotake M, Taniguchi T, Kaneda Y, Ishimoto Y, Ohmori T:Effect of atypical antipsychotics on quality of life in patients with schizophrenia. Annual report of Pharmacopsychiatry research 35:99-105, 2003 (in Japanese)"},{"key":"11","unstructured":"11. Cabinet Office:Annual report on government measures for persons with disabilities. Cabinet Office, Government of Japan, Tokyo, 2018, pp.151-154 (in Japanese)"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tomita K, Takahashi N, Saito S, Maeno N, Iwamoto K, Yoshida K, Kimura H, Iidaka T, Ozaki N:Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry and Clinical Neurosciences 64:62-69, 2010","DOI":"10.1111\/j.1440-1819.2009.02033.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. American Psychiatric Association:The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). American Psychiatric Association, Washington DC, 2013","DOI":"10.1176\/appi.books.9780890425596"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, Fitzpatrick R, Jenkinson C:Self-report quality of life measure for people with schizophrenia:The SQLS. The British Journal of Psychiatry 177:42-46, 2000","DOI":"10.1192\/bjp.177.1.42"},{"key":"15","unstructured":"15. Kaneda Y, Imakura A, Ohmori T:The Japanese version of the Schizophrenia Quality of Life Scale (JSQLS). Clinical Psychiatry 46:737-739, 2004 (in Japanese)"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kaneda Y, Imakura A, Fjii A, Ohmori T:Schizophrenia Quality of Life Scale:validation of the japanese version. Psychiatry Research 113:107-113, 2002","DOI":"10.1016\/S0165-1781(02)00240-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Naber D:A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. International Clinical Psychopharmacology 10:133-138, 1995","DOI":"10.1097\/00004850-199509003-00017"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Naber D, Moritz S, Lambert M, Rajonk F, Holzbach R, Mass R, Andresen B, Frank P, R?diger H, Reinhard M, Burghard A:Improvement of schizophrenic patients\u2019 subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50:79-88, 2001","DOI":"10.1016\/S0920-9964(00)00166-3"},{"key":"19","unstructured":"19. Watanabe M, Matsumura H:Reliability and validity of Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J). Clinical Psychopharmacology 6:905-912, 2003 (in Japanese)"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Crum RM, Anthony JC, Bassett SS, Folstein MF:Population based norms for the Mini-Mental State Examination by age and educational level. Journal of the American Medical Association 269:2386-2391, 1993","DOI":"10.1001\/jama.269.18.2386"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Folstein MF, Folstein SE, McHugh PR:\u201cMINI-MENTAL STATE\u201d A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 12:189-198, 1975","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"22","unstructured":"22. Sugishita M, Hemmi I, Takeuchi T:Reexamination of the validity and reliability of the Japanese version of the Mini-Mental State Examination (MMSE-J). Japanese Journal of Cognitive Neuroscience 18:168-183, 2016 (in Japanese)"},{"key":"23","unstructured":"23. Sugishita M, Koshizuka Y, Sudo S, Sugishita K, Hemmi I, Karasawa H, Ihara M, Asada T, Mihara B:The validity and reliability of the Japanese version of the Mini-Mental State Examination (MMSE-J) with the original procedure of the attention and calculation task (2001). Japanese Journal of Cognitive Neuroscience 20:91-110, 2018 (in Japanese)"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tombaugh TN, McIntyre NJ:The Mini-Mental State Examination:a comprehensive review. Journal of the American Geriatrics Society 40:922-935, 1992","DOI":"10.1111\/j.1532-5415.1992.tb01992.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Addington D, Addington J, Maticka-Tyndale E:Assessing depression in schizophrenia:the Calgary Depression Scale. British Journal of Psychiatry 163:39-44, 1993","DOI":"10.1192\/S0007125000292581"},{"key":"26","unstructured":"26. Kaneda Y, Ohmori T, Addington D:The Japanese version of the Calgary Depression Scale for Schizophrenia (JCDSS).Brain and Nerve 52:163-166, 2000 (in Japanese)"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kaneda Y, Fujii A, Ohmori T:Psychometric properties of the Japanese version of the Calgary Depression Scale for Schizophrenia. The Journal of Nervous and Mental Disease 188:237-239, 2000","DOI":"10.1097\/00005053-200004000-00008"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Overall JE, Gorham DR:The Brief Psychiatric Rating Scale. Psychological Reports 10:799-812, 1962","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"29","unstructured":"29. Overall JE, Gorham DR:The Brief Psychiatric Rating Scale (BPRS):recent developments in ascertainment and scaling. Psychopharmacology Bulletin 24:97-99, 1988"},{"key":"30","unstructured":"30. Rhoades HN, Overall JE:The semistructured BPRS interview and rating guide. Psychopharmacology Bulletin 24:101-104, 1988"},{"key":"31","unstructured":"31. Miyata R, Fujii Y, Inagaki A, Inada T, Yagi G:Reliability of the Japanese version of Brief Psychiatric Rating Scale (BPRS). Clinical Evaluation 23:357-367, 1995 (in Japanese)"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Nicholson IR, Chapman JE, Neufeld RWJ:Variability in BPRS definitions of positive and negative symptoms. Schizophrenia Research 17:177-185, 1995","DOI":"10.1016\/0920-9964(94)00088-P"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Meltzer HY, Burnett S, Bastani B, Ramirez LF:Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital & Community Psychiatry 41:892-897, 1990","DOI":"10.1176\/ps.41.8.892"},{"key":"34","unstructured":"34. Inada T:Evaluation and diagnosis of drug-induced extrapyramidal symptoms:commentary on the DIEPSS and guide to its usage. Seiwa Shoten Publishers, Tokyo, 1996 (in Japanese)"},{"key":"35","unstructured":"35. Inada T:Guidebook to master the DIEPSS, the revised version of \u201cEvaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms\u201d:commentary on the DIEPSS and its usage. Seiwa Shoten Publishers, Tokyo, 2012 (in Japanese)"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Dickerson FB, Ringel NB, Parente F:Subjective quality of life in out-patients with schizophrenia:clinical and utilization correlates. Acta Psychiatrica Scandinavica, 98:124-127, 1988","DOI":"10.1111\/j.1600-0447.1998.tb10053.x"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, de Castella AR, Rolfe T, Davey P, Kulkarni J:Subject and obsever-rated quality of life in schizophrenia. Acta Psychiatrica Scandinavica, 103:387-392, 2001","DOI":"10.1034\/j.1600-0447.2001.00254.x"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P:Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatrica Scandinavica, 108:297-303, 2003","DOI":"10.1034\/j.1600-0447.2003.00132.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Norman RMG, Malla AK, McLean T, Voruganti LPN, Cortese L, McIntosh E, Cheng S, Rickwood A:The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatrica Scandinavica, 102:303-309, 2000","DOI":"10.1034\/j.1600-0447.2000.102004303.x"},{"key":"40","unstructured":"40. Ohmori T:Pharmacotherapy for schizophrenia with a view to cognitive function and QOL. Psychiatria et Neurologia Japonica 113:111-116, 2011 (in Japanese)"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Green MF:Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. Journal of clinical psychiatry 67:3-8, 2006","DOI":"10.4088\/JCP.1006e12"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Green MF:What are the functional consequences of neurocognitive deficits in schizophrenia?. American Journal of Psychiatry 153:321-330, 1996","DOI":"10.1176\/ajp.153.3.321"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Green MF, Kern RS, Braff DL, Mintz J:Neurocognitive deficits and functional outcome in schizophrenia:Are we measuring the \u201cright stuff\u201d? Schizophrenia Bulletin 26:119-136, 2000","DOI":"10.1093\/oxfordjournals.schbul.a033430"}],"container-title":["The Journal of Medical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/69\/1.2\/69_80\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T06:14:58Z","timestamp":1650694498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/69\/1.2\/69_80\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":43,"journal-issue":{"issue":"1.2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2152\/jmi.69.80","relation":{},"ISSN":["1343-1420","1349-6867"],"issn-type":[{"value":"1343-1420","type":"print"},{"value":"1349-6867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}